Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts
- PMID: 18838480
- DOI: 10.3324/haematol.13405
Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts
Abstract
The classification of myelodysplastic syndromes is based on the morphological criteria proposed by the French-American-British (FAB) and World Health Organization (WHO) groups. Accurate enumeration of blast cells, although essential for diagnosis of myelodysplastic syndrome and for assignment to prognostic groups, is often difficult, due to imprecise criteria for the morphological definition of blasts and promyelocytes. An International Working Group on Morphology of Myelodysplastic Syndrome (IWGM-MDS) of hematopathologists and hematologists expert in the field of myelodysplastic syndrome reviewed the morphological features of bone marrows from all subtypes of myelodysplastic syndrome and agreed on a set of recommendations, including recommendations for the definition and enumeration of blast cells and ring sideroblasts. It is recommended that (1) agranular or granular blast cells be defined (replacing the previous type I, II and III blasts), (2) dysplastic promyelocytes be distinguished from cytologically normal promyelocytes and from granular blast cells, (3) sufficient cells be counted to give a precise blast percentage, particularly at thresholds that are important for diagnosis or prognosis and (4) ring sideroblasts be defined as erythroblasts in which there are a minimum of 5 siderotic granules covering at least a third of the nuclear circumference. Clear definitions and a differential count of a sufficient number of cells is likely to improve precision in the diagnosis and classification of myelodysplastic syndrome. Recommendations should be applied in the context of the WHO classification.
Similar articles
-
A comparative review of classification systems in myelodysplastic syndromes (MDS).Semin Oncol. 2005 Aug;32(4 Suppl 5):S3-10. doi: 10.1053/j.seminoncol.2005.06.021. Semin Oncol. 2005. PMID: 16085011 Review.
-
The myelodysplastic syndromes: classification and prognosis.Curr Hematol Rep. 2003 May;2(3):179-85. Curr Hematol Rep. 2003. PMID: 12901338 Review.
-
Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.Pathobiology. 2007;74(2):97-114. doi: 10.1159/000101709. Pathobiology. 2007. PMID: 17587881 Review.
-
Proposals for the classification of the myelodysplastic syndromes.Br J Haematol. 1982 Jun;51(2):189-99. Br J Haematol. 1982. PMID: 6952920
-
The clinical implications of the World Health Organization's classification of myelodysplastic syndromes.Curr Hematol Rep. 2005 May;4(3):175-81. Curr Hematol Rep. 2005. PMID: 15865868 Review.
Cited by
-
Exploring the mechanistic link between SF3B1 mutation and ring sideroblast formation in myelodysplastic syndrome.Sci Rep. 2022 Aug 26;12(1):14562. doi: 10.1038/s41598-022-18921-2. Sci Rep. 2022. PMID: 36028755 Free PMC article.
-
When splicing turns bad.Haematologica. 2012 Jan;97(1):1. doi: 10.3324/haematol.2011.060996. Haematologica. 2012. PMID: 22210325 Free PMC article. No abstract available.
-
Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions.Haematologica. 2019 Oct;104(10):1935-1949. doi: 10.3324/haematol.2019.222059. Epub 2019 May 2. Haematologica. 2019. PMID: 31048353 Free PMC article. Review.
-
Flow cytometry immunophenotyping for diagnosis of myelodysplastic syndrome.Haematologica. 2009 Aug;94(8):1041-3. doi: 10.3324/haematol.2009.007682. Haematologica. 2009. PMID: 19644135 Free PMC article.
-
Chronic myelomonocytic leukemia with ring sideroblasts/SF3B1 mutation presents with low monocyte count and resembles myelodysplastic syndromes with-RS/SF3B1 mutation in terms of phenotype and prognosis.Front Oncol. 2024 Jul 1;14:1385987. doi: 10.3389/fonc.2024.1385987. eCollection 2024. Front Oncol. 2024. PMID: 39011475 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
